VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...
Department of Clinical Laboratory, The Second Affiliated Hospital of Dalian Medical University, Liaoning, China Epstein–Barr virus-associated T/Natural Killer-cell lymphoproliferative disorders (EBV-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback